Vision Sciences (CGNT) Downgraded by Zacks Investment Research to Hold

Vision Sciences (NASDAQ:CGNT) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Cogentix Medical, Inc. is a medical device company which designs, develops, manufactures and markets proprietary technologies serving the urology market. The company’s primary product consists of Urgent(R) PC Neuromodulation System and EndoSheath System. It operates primarily in Orangeburg, New York, The Netherlands and the United Kingdom. Cogentix Medical, Inc., formerly known as Vision-Sciences Inc., is headquartered in Orangeburg, New York. “

Several other research analysts also recently issued reports on CGNT. Aegis downgraded shares of Vision Sciences from a “buy” rating to a “hold” rating and set a $4.75 price objective on the stock. in a report on Tuesday, March 13th. Roth Capital lowered shares of Vision Sciences from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a research report on Friday, March 23rd. Three analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $4.50.



NASDAQ:CGNT opened at $3.84 on Tuesday. Vision Sciences has a 52-week low of $1.55 and a 52-week high of $3.92. The stock has a market cap of $235.71, a PE ratio of -384.00 and a beta of 0.58.

Several institutional investors have recently modified their holdings of CGNT. Meitav Dash Investments Ltd. acquired a new stake in shares of Vision Sciences during the 4th quarter valued at about $1,891,000. White Pine Capital LLC boosted its position in shares of Vision Sciences by 233.1% during the 4th quarter. White Pine Capital LLC now owns 244,500 shares of the medical device company’s stock valued at $770,000 after acquiring an additional 171,100 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Vision Sciences by 12.7% during the 4th quarter. Renaissance Technologies LLC now owns 708,637 shares of the medical device company’s stock valued at $2,232,000 after acquiring an additional 79,900 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Vision Sciences during the 3rd quarter valued at about $152,000. Finally, Millennium Management LLC boosted its position in shares of Vision Sciences by 23.4% during the 4th quarter. Millennium Management LLC now owns 104,343 shares of the medical device company’s stock valued at $329,000 after acquiring an additional 19,753 shares in the last quarter. Institutional investors and hedge funds own 14.52% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Vision Sciences (CGNT) Downgraded by Zacks Investment Research to Hold” was originally reported by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://dakotafinancialnews.com/2018/04/12/vision-sciences-cgnt-downgraded-by-zacks-investment-research-to-hold.html.

About Vision Sciences

Cogentix Medical, Inc, a medical device company, designs, develops, manufactures, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide. The company offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use.

Get a free copy of the Zacks research report on Vision Sciences (CGNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vision Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vision Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply